Growth Equity Opportunities 18 VGE, LLC 13D and 13G filings for X4 Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-05-26 3:03 pm Purchase | 2023-05-18 | 13D | X4 Pharmaceuticals, Inc. XFOR | Growth Equity Opportunities 18 VGE, LLC | 524,760 9.990% | 120,200 (+29.71%) | Filing |
| 2022-12-19 5:31 pm Purchase | 2022-12-09 | 13D | X4 Pharmaceuticals, Inc. XFOR | Growth Equity Opportunities 18 VGE, LLC | 404,560 9.990% | 175,288 (+76.45%) | Filing |
| 2022-07-19 5:28 pm Purchase | 2022-07-06 | 13D | X4 Pharmaceuticals, Inc. XFOR | Growth Equity Opportunities 18 VGE, LLC | 229,272 9.900% | 229,272 (New Position) | Filing |